-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Silence Therapeutics Welcomes Deep Track Capital as New Shareholder
Silence Therapeutics Welcomes Deep Track Capital as New Shareholder
1 December 2021
LONDON, Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that Deep Track Capital, a U.S. investment firm focused exclusively on the life sciences industry, purchased approximately $22 million of American Depository Shares (ADSs) in Silence from existing shareholders.
Gerard Smith, M.D., Principal at Deep Track Capital, said: "Silence has a promising wholly-owned clinical stage pipeline in addition to its proprietary mRNAi GOLD™ platform that we believe could drive long term growth and value creation for patients and shareholders. We look forward to supporting the Silence team in the journey ahead."
Mark Rothera, President and Chief Executive Officer at Silence, said: "We are excited to have Deep Track Capital's support as we initiate our next phase of growth based on maximizing the opportunity of our proprietary mRNAi GOLD™ platform. Next year is set to be another big year for the Company, starting with topline data from our wholly owned SLN360 program for high lipoprotein(a) anticipated in the first quarter of 2022."
Craig Tooman, Chief Financial Officer at Silence, said: "Yesterday marked our first day of trading exclusively on Nasdaq, a move we made to support increasing interest from new investors. We are very pleased to have Deep Track Capital join our expanding U.S. institutional shareholder base and expect this trend to continue."
Enquiries:
Silence Therapeutics plc Gem Hopkins, Head of IR and Corporate Communications ir@silence-therapeutics.com | Tel: +1 (646) 637-3208 |
European PR Consilium Strategic Communications Mary-Jane Elliott/ Angela Gray / Chris Welsh silencetherapeutics@consilium-comms.com | Tel: +44 (0) 20 3709 5700 |
About Silence Therapeutics
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet need. Silence's proprietary mRNAi GOLD™ platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address iron-loading anemia conditions. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Hansoh Pharma, among others. For more information, please visit .
Forward-Looking Statements
Certain statements made in this announcement are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other securities laws, including with respect to the Company's clinical and commercial prospects and the anticipated timing of data reports from the Company's clinical trials. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements, including those risks identified in the Company's most recent Admission Document and its amended Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on April 29, 2021. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.
1 December 2021
2021年12月1日
LONDON, Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that Deep Track Capital, a U.S. investment firm focused exclusively on the life sciences industry, purchased approximately $22 million of American Depository Shares (ADSs) in Silence from existing shareholders.
亞洲網倫敦、沉默治療公司、納斯達克:發現、開發和交付新型短干擾核糖核酸療法的領先企業SLN(以下簡稱“沉默公司”或“本公司”)今天宣佈,專門關注生命科學行業的美國投資公司Deep Track Capital從現有股東手中購買了沉默公司價值約2,200萬美元的美國存托股票(ADS)。
Gerard Smith, M.D., Principal at Deep Track Capital, said: "Silence has a promising wholly-owned clinical stage pipeline in addition to its proprietary mRNAi GOLD™ platform that we believe could drive long term growth and value creation for patients and shareholders. We look forward to supporting the Silence team in the journey ahead."
傑拉德·史密斯、M.D., 校長 在… 深軌資本,表示:除了其專有的mRNAi黃金™平台外,思萊斯公司還擁有一條前景看好的全資臨牀階段管道。我們相信,這一平台可以推動患者和股東的長期增長和價值創造。我們期待着在未來的征程中支持斯萊恩斯公司的團隊。“
Mark Rothera, President and Chief Executive Officer at Silence, said: "We are excited to have Deep Track Capital's support as we initiate our next phase of growth based on maximizing the opportunity of our proprietary mRNAi GOLD™ platform. Next year is set to be another big year for the Company, starting with topline data from our wholly owned SLN360 program for high lipoprotein(a) anticipated in the first quarter of 2022."
馬克·羅瑟拉(Mark Rothera),總裁兼首席執行官Hief行政主任 在…靜默,説他説:“我們很高興得到Deep Track Capital的支持,因為我們在最大限度地利用我們專有的mRNAi Gold™平台的機會的基礎上開始了下一階段的增長。明年對公司來説將是又一個重要的一年,從我們全資擁有的SLN360高脂蛋白(A)項目的背線數據開始,預計將在2022年第一季度進行。”
Craig Tooman, Chief Financial Officer at Silence, said: "Yesterday marked our first day of trading exclusively on Nasdaq, a move we made to support increasing interest from new investors. We are very pleased to have Deep Track Capital join our expanding U.S. institutional shareholder base and expect this trend to continue."
首席財務官克雷格·圖曼(Craig Tooman)在… 沉默,説昨天是我們在納斯達克獨家交易的第一天,我們採取這一舉措是為了支持新投資者日益增長的興趣。我們非常高興深軌資本加入我們不斷擴大的美國機構股東基礎,並預計這一趨勢將繼續下去。
Enquiries:
查詢:
Silence Therapeutics plc Gem Hopkins, Head of IR and Corporate Communications ir@silence-therapeutics.com |
Tel: +1 (646) 637-3208 |
European PR Consilium Strategic Communications Mary-Jane Elliott/ Angela Gray / Chris Welsh silencetherapeutics@consilium-comms.com |
Tel: +44 (0) 20 3709 5700 |
沉默治療公司 吉姆·霍普金斯(Gem Hopkins),投資者關係和企業公關主管 電子郵箱:ir@Silence-Treateutics.com |
電話:+1(646)637-3208 |
歐洲人PR Consilium戰略傳播 瑪麗-簡·埃利奧特/安吉拉·格雷/克里斯·威爾士 郵箱:silenceTreateutics@conconlium-comms.com |
電話:+44(0)2037095700 |
About Silence Therapeutics
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet need. Silence's proprietary mRNAi GOLD™ platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address iron-loading anemia conditions. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Hansoh Pharma, among others. For more information, please visit .
關於沉默療法
沉默治療公司正在開發新一代藥物,方法是利用人體自然的RNA干擾(RNAi)機制,抑制特定靶基因的表達,這些基因被認為在有重大未得到滿足的需求的疾病的病理中發揮作用。Silent公司專有的mRNAi金™平台可以用來創建siRNA(短干擾RNA),它可以精確地針對肝臟中的疾病相關基因並使其沉默,這代表着一個巨大的機會。SILE公司全資擁有的候選產品包括SLN360和SLN124。SLN360旨在滿足在降低天生高水平脂蛋白(A)人羣心血管風險方面的高和普遍的未得到滿足的醫療需求,SLN124旨在解決鐵負荷貧血症問題。沉默公司還與阿斯利康公司、美林製藥公司和漢索製藥公司等公司保持着持續的研發合作。有關更多信息,請訪問。
Forward-Looking Statements
Certain statements made in this announcement are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other securities laws, including with respect to the Company's clinical and commercial prospects and the anticipated timing of data reports from the Company's clinical trials. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements, including those risks identified in the Company's most recent Admission Document and its amended Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on April 29, 2021. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.
前瞻性陳述
本公告中的某些陳述屬於“1995年美國私人證券訴訟改革法”和其他證券法所指的前瞻性陳述,包括與公司的臨牀和商業前景以及公司臨牀試驗數據報告的預期時間有關的陳述。這些前瞻性陳述不是歷史事實,而是基於該公司目前對其行業的預期、估計和預測、其信念和假設。諸如“預期”、“期望”、“打算”、“計劃”、“相信”、“尋求”、“估計”等詞彙以及類似的表達方式都是為了識別前瞻性陳述。這些陳述不是對未來業績的保證,會受到已知和未知的風險、不確定性和其他因素的影響,其中一些是公司無法控制的,很難預測,可能會導致實際結果與前瞻性陳述中表達或預測的結果大不相同,包括公司最近的承認文件及其於2021年4月29日提交給美國證券交易委員會的修訂的20-F表格年度報告中確定的風險。公司告誡證券持有人和潛在的證券持有人不要過度依賴這些前瞻性陳述,這些陳述僅反映公司截至本公告日期的觀點。本公告中所作的前瞻性陳述僅涉及截至該陳述發表之日的事件。除非法律或任何適當的監管機構要求,否則公司不承擔任何義務公開發布對這些前瞻性陳述的任何修訂或更新,以反映本公告發布之日之後發生的事件、情況或意想不到的事件。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧